RT Journal Article
T1 Changes in Liver Lipidomic Profile in G2019S-LRRK2 Mouse Model of Parkinson’s Disease
A1 Yakhine Diop, Sokhna M. S.
A1 Moreno Cruz, Paula
A1 Manrique García, Laura
A1 Gabrielly Pereira, Amanda
A1 Morales García, José Ángel
A1 Corral Nieto, Yaiza
A1 Niso Santano, Mireia
A1 González Polo, Rosa A.
A1 Uribe Carretero, Elisabet
A1 Durand, Sylvère
A1 Maiuri, Maria Chiara
A1 Paredes Barquero, Marta
A1 Alegre Cortés, Eva
A1 Canales Cortés, Saray
A1 López de Munain, Adolfo
A1 Pérez Tur, Jordi
A1 Pérez Castillo, Ana
A1 Kroemer, Guido
A1 Fuentes, José M.
A1 Bravo San Pedro, José M.
AB The identification of Parkinson’s disease (PD) biomarkers has become a main goal for the diagnosis of this neurodegenerative disorder. PD has not only been intrinsically related to neurological problems, but also to a series of alterations in peripheral metabolism. The purpose of this study was to identify metabolic changes in the liver in mouse models of PD with the scope of finding new peripheral biomarkers for PD diagnosis. To achieve this goal, we used mass spectrometry technology to determine the complete metabolomic profile of liver and striatal tissue samples from WT mice, 6-hydroxydopamine-treated mice (idiopathic model) and mice affected by the G2019S-LRRK2 mutation in LRRK2/PARK8 gene (genetic model). This analysis revealed that the metabolism of carbohydrates, nucleotides and nucleosides was similarly altered in the liver from the two PD mouse models. However, long-chain fatty acids, phosphatidylcholine and other related lipid metabolites were only altered in hepatocytes from G2019S-LRRK2 mice. In summary, these results reveal specific differences, mainly in lipid metabolism, between idiopathic and genetic PD models in peripheral tissues and open up new possibilities to better understand the etiology of this neurological disorder.
PB MDPI
SN 2073-4409
YR 2023
FD 2023
LK https://hdl.handle.net/20.500.14352/72403
UL https://hdl.handle.net/20.500.14352/72403
LA eng
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO Instituto de Salud Carlos III
NO Centre for Networked Biomedical Research in Neurodegenerative Diseases
DS Docta Complutense
RD 14 jun 2026